JPRN-UMIN000013454已完成2 期
Efficacy and safety study of defibrotide (DF) for the treatment of venoocclusive disease (VOD). - Efficacy and safety study of defibrotide (DF) for the treatment of venoocclusive disease (VOD).
Fukushima Medical University Hospital Atsushi Kikuta0 个研究点目标入组 20 人开始时间: 2014年3月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Using medication that increases risk of hemorrhage. 2.Acute bleeding that is not controlled. 3.Unstable hemodynamic status that require more than one vasopressor or decreased mean atrial pressure (MAP). 4.Complicated with viral fulminant hepatitis 5.Past history of organ transplant other than hematopoietic cell transplant. 6.Complicated with Grade IV GVHD 7.Females with pregnancy, breastfeeding, possible pregnancy.Patient who will not consent contraception 8.Judged as inappropriate for participating in the study by the principal or other investigator for other reasons.
研究者
相似试验
已完成
不适用
Efficacy and safety study of defibrotide (DF) for the prophylaxis of venoocclusive disease (VOD).Veno Occlusive DiseaseJPRN-UMIN000013455Fukushima Medical University Hospital Atsushi Kikuta75
已完成
1 期
Clinical study of defibrotide in safety and pharmacokinetics in healthy adult subjectsVeno Occulisive DiseaseJPRN-UMIN000009591Fukushima Medical University Clinical Oncology Center, Division of Pediatric Oncology, Atsushi Kikuta20
已完成
不适用
The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancerProstate cancerJPRN-UMIN000015130Keio University School of Medicine, Department of Urology20
尚未招募
不适用
Clinical investigation of the effectiveness of different mouth rinses in Covid-19-PatientsCOVID-19DRKS00023725niversität Witten/Herdecke Fakultät für Gesundheit (Department für Zahn-, Mund- und Kieferheilkunde)Lehrstuhl für Zahnerhaltung und Präventive Zahnmedizin60
进行中（未招募）
1 期
A study of the benefit and safety of using the drug Deferasirox in patients with increased iron levels who have Myelodysplastic SyndromesIron overload in patients being treated for Myelodysplastic syndroms (MDS) by regular blood transfusionsMedDRA version: 14.1 Level: LLT Classification code 10068361 Term: MDS System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10040310 Term: Serum iron increased System Organ Class: 100000004848EUCTR2011-004559-38-GBniversity of Birmingham13